FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC

Authors: David R. Spigel, Jamie E. Chaft, Scott Gettinger, Bo H. Chao, Luc Dirix, Peter Schmid, Laura Q.M. Chow, Rodney J. Hicks, Larry Leon, Jill Fredrickson, Marcin Kowanetz, Alan Sandler, Roel Funke, Naiyer A. Rizvi - Journal of Thoracic Oncology 2018 cited by 172